Research programme: T-cell activated therapeutics - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Drug Profile

Research programme: T-cell activated therapeutics - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Alternative Names: Allogeneic T-cell therapies - Atara/MSKCC; CAR T cell therapy - Atara/Memorial Sloan Kettering Cancer Center; CAR-T cells - Atara/MSKCC; Chimeric antigen receptor-modified T-cells - Atara/MSKCC

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Atara Biotherapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Oct 2017 Atara Biotherapeutics plans a phase I trial of allogenic ATA 188 for Multiple sclerosis in USA in the fourth quarter of 2017
  • 23 Sep 2014 Early research in Undefined indication in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top